Wockhardt is a global pharma transitioning from generics to novel antibiotics and biotech, with 77% revenue from emerging markets and UK. Key growth drivers are ZAYNICH (global Phase 3 completed, India launch mid-FY26, US filing Q1 FY26) and Miqnaf (96.7% efficacy, India launch May 2025). Management has repeatedly delayed US FDA filings (ZAYNICH pushed to Q3 FY26) and missed 14 India/25 UK launch targets, though EBITDA margins expanded 500 bps to 14% and net debt fell to ₹64 cr. Biotech capacity will double in 24-36 months to capture Novo Nordisk’s ₹450 cr India diabetes gap, while ZAYNICH’s $9B global TAM hinges on 9-12 month USFDA review. Execution risks remain high due to recurring timeline slips and unproven commercialization of novel antibiotics.
companyname: Wockhardt Limited ticker: WOCKPHARMA sector: Pharmaceuticals / Biotechnology Wockhardt is a global research-driven pharmaceutical and biotechnology company founded in 1967. It employs roughly 2,900 people from 27 nationalities and operates 11 manufacturing facilities along with two R&D centers in India and the UK. Approximately 78% of its global revenue comes from international businesses, with operations spanning India, the UK, Ireland, the US, and emerging markets. The company r...
Read the full report →margin expansion, regulatory approval, new product segment, geographic expansion
No guidance
mixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Wockhardt Limited and 4,900+ companies.
5-day free pass. No card required.